William Blair Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform rating.
Stocks · News reference
Reported Earlier, Rhythm Pharmaceuticals Launches IMCIVREE In Japan As First Approved Therapy For Acquired Hypothalamic Obesity, Backed By Phase 3 TRANSCEND Trial Showing 18.8% Placebo-Adjusted BMI Reduction
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145
HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $130
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $105 to $130.